Related Experiment Video
Updated: Jan 12, 2026

10:16
Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
Published on: October 8, 2015
13.6K
CT-based texture analysis predicts BRAFV600E mutation in calcified papillary thyroid carcinoma
Yongqin Chen1, Wenfu Cao2, Hang Li3
1Department of Pathology, Fujian Medical University Union Hospital, Fuzhou, China.
Frontiers in Oncology
|November 7, 2025
Summary
CT-based texture analysis accurately predicts BRAFV600E mutations in papillary thyroid carcinoma (PTC). This non-invasive method, particularly using nonlinear discriminant analysis (NDA), shows high diagnostic performance for BRAFV600E prediction in calcified PTC.
Area of Science:
- Radiology
- Oncology
- Genetics
Background:
- The BRAF gene is crucial in papillary thyroid carcinoma (PTC) development.
- BRAFV600E mutation is a key driver in PTC pathogenesis.
Purpose of the Study:
- To evaluate computed tomography (CT)-based texture analysis for predicting BRAFV600E mutation in calcified PTC.
- To assess the diagnostic performance of texture features in identifying BRAFV600E status.
Main Methods:
- Texture features were extracted from 475 calcified PTC cases using MaZda software.
- Feature selection algorithms (Fisher, POE+ACC, MI) and classification methods (PCA, LDA, NDA) were employed.
- Diagnostic performance was assessed using receiver operating characteristic (ROC) curves.
Main Results:
- Nonlinear discriminant analysis (NDA) demonstrated superior diagnostic performance compared to PCA and LDA.
- The POE+ACC+NDA and MI+NDA methods achieved high accuracy, with areas under the curve (AUC) of 0.969 (training) and 0.964 (validation).
- Texture analysis of both parenchymal and calcified areas proved effective in predicting BRAFV600E mutation.
Conclusions:
- The POE+ACC+NDA or MI+NDA methods offer high diagnostic performance for predicting BRAFV600E mutation in PTC.
- CT-based texture analysis, especially of calcified areas, is a viable tool for non-invasively predicting BRAFV600E mutation status.

